Metabolic health for patients with prostate cancer during androgen deprivation therapy

Koji Mitsuzuka, Yoichi Arai

Research output: Chapter in Book/Report/Conference proceedingChapter


Androgen deprivation therapy (ADT) continues to be widely used for the treatment of prostate cancer despite the appearance of new-generation androgen receptor-targeting drugs after 2000. ADT can alleviate symptoms in patients with metastatic prostate cancer and may have a survival benefit in some patients, but it causes undesirable changes in lipid and sugar metabolism. Moreover, these metabolic changes could be related to new onset or worsening of diseases such as diabetes mellitus or cardiovascular disease. Several studies examining the influence of ADT in Japanese patients with prostate cancer also showed that metabolic changes such as weight gain, dyslipidemia, or fat accumulation can occur as in patients in Western countries. Efforts to decrease these unfavorable changes and events are important. First, overuse of ADT for localized or elderly prostate cancer patients should be reconsidered. Second, intermittent ADT may be beneficial for selected patients who suffer from impaired quality of life (QOL) due to continuous ADT. Third, education and instruction, such as diet or exercise, to decrease metabolic changes before initiating ADT are important, because metabolic changes can occur in the early ADT period.

Original languageEnglish
Title of host publicationHormone Therapy and Castration Resistance of Prostate Cancer
PublisherSpringer Singapore
Number of pages14
ISBN (Electronic)9789811070136
ISBN (Print)9789811070129
Publication statusPublished - 2018 May 11


  • Androgen deprivation therapy
  • Metabolic change
  • Obesity
  • Prostate cancer
  • Sarcopenia

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Metabolic health for patients with prostate cancer during androgen deprivation therapy'. Together they form a unique fingerprint.

Cite this